The broad contribution of glutamine carbon and nitrogen to cancer metabolism has led to the development of drugs targeting glutamine metabolism such as CB-839, an orally bioavailable GLS inhibitor currently undergoing Phase I evaluation for cancer treatment10, 11, 12. This evidence concerns the gene GLS and cancer.